{"id":"NCT00791102","sponsor":"University of Chicago","briefTitle":"Topical ASP-1001 (Contrast Media Formulation) and the Acute Response to Nasal Allergen Challenge (NAC)","officialTitle":"A Randomized, Double-Blind, Placebo-Controlled, Cross-Over Trial of Topical ASP-1001 (Contrast Media Formulation) in the Prevention of the Signs and Symptoms of the Acute Response to Nasal Allergen Challenge (NAC)","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2010-01","primaryCompletion":"2010-09","completion":"2010-12","firstPosted":"2008-11-14","resultsPosted":"2013-07-10","lastUpdate":"2013-07-10"},"enrollment":20,"design":{"allocation":"RANDOMIZED","model":"CROSSOVER","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Allergic Rhinitis"],"interventions":[{"type":"DRUG","name":"ASP-1001 nasal spray","otherNames":[]},{"type":"DRUG","name":"Placebo for ASP-1001","otherNames":[]}],"arms":[{"label":"1","type":"ACTIVE_COMPARATOR"},{"label":"2","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to see whether ASP-1001 when given as a nasal spray is safe and can reduce the signs and symptoms of allergic rhinitis (hayfever) following nasal challenge with antigen.","primaryOutcome":{"measure":"Change in Sneezing Symptom","timeFrame":"10 minutes after diluent challenge and 10 minutes after each antigen challenge","effectByArm":[{"arm":"Topical ASP-1001","deltaMin":1,"sd":null},{"arm":"Placebo for Topical ASP-1001","deltaMin":1,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Days","sex":"ALL","healthyVolunteers":true,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":20},"commonTop":[]}}